{"id":44635,"date":"2022-06-02T20:02:06","date_gmt":"2022-06-02T18:02:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/"},"modified":"2022-06-02T20:02:06","modified_gmt":"2022-06-02T18:02:06","slug":"resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/","title":{"rendered":"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer"},"content":{"rendered":"
\n

SAN DIEGO & HOUSTON–(BUSINESS WIRE)–National Resilience, Inc.<\/a> (Resilience) and The University of Texas MD Anderson Cancer Center<\/a> today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture will advance its work within a culture of academic innovation alongside industrial expertise.\n<\/p>\n

<\/a><\/p>\n

\nThe Cell Therapy Manufacturing Center will be based in a state-of-the art 60,000-square-foot manufacturing facility in the Texas Medical Center, with a team of 70 employees focused on process and analytical development as well as early-phase and clinical-stage Good Manufacturing Practices (GMP).\n<\/p>\n

\nThe joint venture combines MD Anderson\u2019s expertise in immunotherapy and cell therapies as well as a leading clinical trials infrastructure, with Resilience\u2019s innovative biomanufacturing technologies, advanced analytics and a national network for developing and producing cell therapies. Together, the parties aim to accelerate the path of cell therapies to the clinic, while enabling scalability and a smooth transition to late-phase clinical and commercial activities.\n<\/p>\n

\n\u201cCell therapies have had a dramatic impact for patients with certain cancers, but progress has been hampered by structural challenges,\u201d said Jason Bock, Ph.D., Chief Executive Officer of the Cell Therapy Manufacturing Center. \u201cThis novel joint venture was conceived to address those challenges by harnessing the complementary capabilities of two world-class organizations, allowing us to advance innovative programs to deliver impactful therapies to patients.\u201d\n<\/p>\n

\nThe joint venture will engage with MD Anderson researchers and external industry collaborators to advance new therapies through preclinical and clinical development, ensuring consistent and safe products that can be evaluated rapidly in clinical trials led by MD Anderson physicians. Resilience customers will be able to leverage this offering as part of the company\u2019s growing network of biomanufacturing facilities that are flexible enough to scale projects from small-batch pre-clinical to large-scale commercial production. Resilience has 10 facilities across North America, with more than 1 million square feet of manufacturing space.\n<\/p>\n

\n\u201cThe promise of cell therapies to help patients in need has been limited by a lack of innovation in biomanufacturing,\u201d said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. \u201cThis collaboration aims to overcome those hurdles by extending our network with this unique partnership, creating opportunities to incubate innovative ideas and provide cutting-edge biomanufacturing technologies and processes to researchers, with a goal of bringing more cell therapies to patients.\u201d\n<\/p>\n

\nThe joint venture will advance the most promising cell therapy modalities to answer unmet clinical needs, including engineered tumor infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR)-modified T cells, endogenous T cells (ETCs), engineered natural killer (NK) cells and other emerging technologies, for patients with hematological and solid tumors. MD Anderson researchers are leaders in the field of cancer cell therapy, responsible for advancing the translational and clinical development of many of the currently approved and experimental cell therapies.\n<\/p>\n

\nThe joint venture is built upon MD Anderson\u2019s Biologics Development platform, formerly part of the institution\u2019s Therapeutics Discovery division<\/a>. Current strategic collaborations with MD Anderson\u2019s Biologics Development platform will continue; collaborative relationships with MD Anderson\u2019s Therapeutics Discovery division, as well as physicians and scientists across the institution, also will be maintained.\n<\/p>\n

\n\u201cWe believe in the tremendous potential of cell therapies to deliver solutions that offer cures, not merely prolonged survival. Resilience offers unique capabilities that make it an ideal choice for unlocking that potential and accelerating impactful cell therapies,\u201d said Ferran Prat, Ph.D., J.D., senior vice president for Research Administration and Industry Relations at MD Anderson. \u201cOur mission at MD Anderson is to end cancer, and this joint venture is a strategic step toward realizing that goal.\u201d\n<\/p>\n

\nAbout MD Anderson<\/b>\n<\/p>\n

\nThe University of Texas MD Anderson Cancer Center<\/a> in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution\u2019s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 52 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Report\u2019s \u201cBest Hospitals\u201d rankings. It has been named one of the nation\u2019s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).\n<\/p>\n

\nAbout Resilience<\/b>\n<\/p>\n

\nResilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients\u2019 lives by continuously advancing the science of biopharmaceutical manufacturing and development. For more information, visit www.Resilience.com<\/a> and follow us on social media: @IncResilience<\/a> on Twitter and Resilience<\/a> on LinkedIn.\n<\/p>\n

\nDisclosure<\/b>\n<\/p>\n

\nMD Anderson has an institutional conflict of interest with National Resilience, Inc. and the Cell Therapy Manufacturing Center, and these relationships will be managed according to an MD Anderson Institutional Conflict of Interest Management and Monitoring Plan.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts:<\/b>\n<\/p>\n

\nResilience<\/b>
Ryan Flinn<\/b>
Head of Communications, Resilience
\n
Ryan.flinn@resilience.com<\/a>
510-207-7616\n<\/p>\n

\nMD Anderson<\/b>
Clayton Boldt, Ph.D.
\n
Public Relations
\n
crboldt@mdanderson.org<\/a>
713-792-9518\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO & HOUSTON–(BUSINESS WIRE)–National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-44635","format-standard","category-industry"],"yoast_head":"\nResilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO & HOUSTON–(BUSINESS WIRE)–National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-02T18:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220602005856\/en\/1475034\/21\/Resilience_Logotype_RGB_Black.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer\",\"datePublished\":\"2022-06-02T18:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/\"},\"wordCount\":908,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005856\\\/en\\\/1475034\\\/21\\\/Resilience_Logotype_RGB_Black.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/\",\"name\":\"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005856\\\/en\\\/1475034\\\/21\\\/Resilience_Logotype_RGB_Black.jpg\",\"datePublished\":\"2022-06-02T18:02:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005856\\\/en\\\/1475034\\\/21\\\/Resilience_Logotype_RGB_Black.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005856\\\/en\\\/1475034\\\/21\\\/Resilience_Logotype_RGB_Black.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer - Pharma Trend","og_description":"SAN DIEGO & HOUSTON–(BUSINESS WIRE)–National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-02T18:02:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220602005856\/en\/1475034\/21\/Resilience_Logotype_RGB_Black.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer","datePublished":"2022-06-02T18:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/"},"wordCount":908,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005856\/en\/1475034\/21\/Resilience_Logotype_RGB_Black.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/","url":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/","name":"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005856\/en\/1475034\/21\/Resilience_Logotype_RGB_Black.jpg","datePublished":"2022-06-02T18:02:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220602005856\/en\/1475034\/21\/Resilience_Logotype_RGB_Black.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220602005856\/en\/1475034\/21\/Resilience_Logotype_RGB_Black.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/resilience-and-md-anderson-launch-joint-venture-to-accelerate-development-and-manufacturing-of-innovative-cell-therapies-for-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44635"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44635\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}